Abstract:Background: The relationship between genotype and phenotype is governed by numerous genetic interactions (GIs), and the mapping of GI networks is of interest for two main reasons: 1) By modelling biological robustness, GIs provide a powerful opportunity to infer compensatory biological mechanisms via the identification of functional relationships between genes, which is of interest for biological discovery and translational research. Biological systems have evolved to compensate for genetic (i.e., variations and mutations) and environmental (i.e., drug efficacy) perturbations by exploiting compensatory relationships between genes, pathways and biological processes; 2) GI facilitates the identification of the direction (alleviating or aggravating interactions) and magnitude of epistatic interactions that influence the phenotypic outcome. The generation of GIs for human diseases is impossible using experimental biology approaches such as systematic deletion analysis. Moreover, the generation of disease-specific GIs has never been undertaken in humans. Methods: We used our Indian schizophrenia case-control (case-816, controls-900) genetic dataset to implement the workflow. Standard GWAS sample quality control procedure was followed. We used the imputed genetic data to increase the SNP coverage to analyse epistatic interactions across the genome comprehensively. Using the odds ratio (OR), we identified the GIs that increase or decrease the risk of a disease phenotype. The SNP-based epistatic results were transformed into gene-based epistatic results. Results: We have developed a novel approach by conducting gene-based statistical epistatic analysis using an Indian schizophrenia case-control genetic dataset and transforming these results to infer GIs that increase the risk of schizophrenia. There were ∼9.5 million GIs with a p -value ≤ 1 × 10 −5 . Approximately 4.8 million GIs showed an increased risk (OR > 1.0), while ∼4.75 million GIs had a decreased risk (OR <1.0) for schizophrenia. Conclusion: Unlike model organisms, this approach is specifically viable in humans due to the availability of abundant disease-specific genome-wide genotype datasets. The study exclusively identified brain/nervous system-related processes, affirming the findings. This computational approach fills a critical gap by generating practically non-existent heritable disease-specific human GIs from human genetic data. These novel datasets can train innovative deep-learning models, potentially surpassing the limitations of conventional GWAS.

The Future of Genetic Studies of Complex Human Diseases

Combining Hipscs and Human Genetics: Major Applications in Drug Development.

Modeling the complex genetic architectures of brain disease

Strategies to Identify Genes for Complex Diseases.

Genome-wide association studies for complex traits: consensus, uncertainty and challenges

Genome-wide Causation Studies of Complex Diseases

Single nucleotide polymorphisms and the future of genetic epidemiology

Genetic interactions of schizophrenia using gene-based statistical epistasis exclusively identify nervous system-related pathways and key hub genes

Unraveling schizophrenia's genetic complexity through advanced causal inference and chromatin 3D conformation

Application of Genomewide Association Studies in Complex Human Disease

Strategies and Methods to Identify Genes for Complex Diseases

Research in schizophrenia using genome-wideassociation study methodology

Probability Theory-Based SNP Association Study Method for Identifying Susceptibility Loci and Genetic Disease Models in Human Case-Control Data

The genomic case against genetic determinism

Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism

A brief history of human disease genetics

Schizophrenia genomics: genetic complexity and functional insights

Advances in Molecular Genetics of Schizophrenia

Synergistic effects of common schizophrenia risk variants

Progress in the Studies on the Molecular Genetics of Schizophrenia

High-throughput CRISPRi and CRISPRa technologies in 3D genome regulation for neuropsychiatric diseases